Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cytek Biosciences Narrows FY24 Revenue Outlook From $203M - $213M To $203M - $210M, Est $208.801M; Now Expects To Report Net Loss In The Single Digit Millions For FY24

Author: Benzinga Newsdesk | August 06, 2024 05:21pm

In addition, Cytek expects to report a net loss in the single digit millions for the full year 2024 (prior view: report positive net income) due to an outlook of slightly lower gross profit, higher than expected stock-based compensation, and lower other income.

Cytek expects to generate positive cash flow from operations in 2024.

Posted In: CTKB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist